(MENAFN- Baystreet.ca)
Merck to Buy Acceleron
Merck (NYSE:MRK) will buy drugmaker Acceleron Pharma for about $11.5 billion, the companies said on Thursday, as the U.S. pharmaceutical giant looks to beef up its portfolio with drugs for rare diseases.
Merck will pay $180 per Acceleron share in cash, representing a premium of about 2.6% to the stock's closing price on Wednesday, according to Refinitiv data.
The deal gives Merck, which makes the blockbuster cancer drug Keytruda, access to a potentially lucrative rare disease drug candidate, sotatercept.
Cambridge, Massachusetts-based Acceleron focuses on therapeutics that treat cardiovascular and other blood-related disorders. Its sotatercept drug, which is currently in a late-stage study, is aimed at treating a rare cardiovascular disease called pulmonary arterial hypertension (PAH), a type of high blood pressure that affects the lungs.
The market for treatments targeting rare diseases has become lucrative, as drugmakers typically charge higher prices for drugs that serve small patient populations.
An estimated 25-30 million Americans are living with a rare disease, according to the U.S. National Institute Of Health, prompting a number of drugmakers to eye that slice of the market.
Along with sotatercept, Merck will gain access to Reblozyl, which is approved for the treatment of two blood-related disorders, including anemia in patients with beta thalassemia.
“Although the acquisition of Acceleron will not fully remove the overhang of generic competition for MRK's single largest drug Keytruda (we estimate 37% of 2021 sales), it does help diversify sales, which addresses a large shareholder concern,” Cantor Fitzgerald analyst Louise Chen said in a client note.
MRK shares grew $1.10, or 1.5%, to $76.19
MENAFN30092021000212011056ID1102894924
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.